💸 The Tape

Pennsylvania has everything it needs to legalize adult-use cannabis — the public support, the economic imperative, the neighboring-state pressure, and a governor who's been asking for it for three straight years. What it doesn't have is a Senate willing to let it happen.

And as of this week, the obstacle has a new face. Republican gubernatorial candidate Stacy Garrity, the state's current Treasurer, said she is opposed to legalizing recreational marijuana and would veto any bill to do so if elected governor. It's a declaration that adds another layer of uncertainty to an already gridlocked legalization effort — and one that sharpens the stakes of November's election for the cannabis industry.

Meanwhile, the Republican leadership that actually controls the Senate right now hasn't budged. Senate Majority Leader Joe Pittman (R) remains the primary obstacle, stating: "I do not see a prevailing view for legalization of recreational marijuana within our caucus as part of the current budget." Senate President Pro Tempore Kim Ward (R) has long opposed recreational legalization and has repeatedly questioned the mechanics of state involvement in a cannabis market, asking pointedly how the state would pay employees "with money that is coming from a federally illegal entity."

That federal argument, it's worth noting, just got significantly weaker. The Trump administration's rescheduling of state-licensed medical cannabis to Schedule III — effective April 22 — directly undermines the "federal conflict" rationale that Pennsylvania Senate Republicans have leaned on for years. Cannabis is no longer classified alongside heroin. The DEA is actively registering medical dispensaries. The legal landscape has fundamentally shifted. And yet, the Senate's position hasn't moved an inch.

The Legislative Graveyard

The recent history of cannabis legislation in Pennsylvania reads like a case study in institutional paralysis.

In May 2025, the Democratic-controlled House passed HB 1200 by the narrowest possible margin — 102 to 101 — on a strict party-line vote. The bill proposed a novel model: adult-use cannabis sold through state-operated stores overseen by the Pennsylvania Liquor Control Board, similar to how the commonwealth handles liquor. Within a week, the Senate Law and Justice Committee killed it in a 7-3 vote.

Senate Republicans didn't just oppose the bill — they mocked it. Sen. Dan Laughlin (R-Erie), who chairs the committee and is himself a legalization supporter, called it "dead on arrival" and declared that "a state-store model for adult-use cannabis will not pass the Senate. That's not an opinion, it's a fact."

The irony is that bipartisan alternatives exist. Laughlin and Sen. Sharif Street (D) introduced SB 120, a private retail model with a 14% combined tax rate, possession limits of 30 grams, and a $100,000 conversion fee for existing medical operators. Reps. Emily Kinkead (D) and Abby Major (R) filed HB 20, another private retail bill with a 13% tax rate and 60 social equity permits. Both bills use the kind of privately-run, state-licensed framework that Senate Republicans claim to prefer. Neither has been scheduled for a hearing.

The Money Problem Pennsylvania Can't Ignore

If the political arguments for legalization aren't moving the needle, the fiscal ones are getting harder to dismiss.

Governor Josh Shapiro has included cannabis legalization in each of his last three budget proposals. His administration projects the state would generate more than $729 million in its first year — the bulk from one-time licensing fees — with annual tax revenue exceeding $200 million once fully implemented. The state's Independent Fiscal Office projects even higher numbers, estimating annual revenue reaching $432 million by 2030-2031.

Those aren't hypothetical dollars. Pennsylvania is staring down a $5.1 billion structural deficit, with the state's rainy day fund projected to be largely depleted by the 2027-28 fiscal year. The House recently passed Shapiro's budget plan — which relies in part on projected cannabis revenue — but the Senate's Republican leadership expressed "profound concerns" about spending levels without engaging on the revenue solution sitting right in front of them.

Meanwhile, five of Pennsylvania's six neighboring states have legalized adult-use cannabis. Up to 60% of customers at border-state dispensaries are reportedly Pennsylvania residents. Every dollar those consumers spend in New Jersey, New York, Ohio, or Maryland is revenue Pennsylvania chose to forfeit.

The Medical Foundation

What makes Pennsylvania's inaction particularly frustrating is that the state already has one of the most robust medical cannabis programs in the country. With more than 439,000 registered patients, 185 dispensaries, and over $1.7 billion in annual sales, the infrastructure for adult-use expansion is essentially built. The cultivation facilities exist. The retail networks exist. The regulatory framework exists. The only thing missing is the legislative permission to serve a broader consumer base.

Federal rescheduling makes that existing medical infrastructure even more valuable. With 280E tax relief now applying to Schedule III medical operations, Pennsylvania's licensed operators are about to see meaningful improvements to their after-tax profitability — but only on the medical side. Adult-use revenue, which would dramatically expand the addressable market, remains locked behind the Senate's refusal to act.

The Election Factor

Garrity's veto pledge introduces an uncomfortable variable into the 2026 calculation. While Governor Shapiro holds a commanding lead in polling — a 22-point advantage in a recent Susquehanna Polling survey with just 5% undecided — the fact that the Republican candidate is running explicitly against legalization means a Shapiro loss would close the door entirely for the foreseeable future.

Garrity herself acknowledged the political reality, saying of legalization: "They're never going to pass it. Not as long as Senate Republicans are in control of the Senate." She's probably right about the current session. But her willingness to promise a veto signals that even if Senate dynamics eventually shift, a Republican governor would block reform regardless.

Where This Leaves Things

Seven out of ten Pennsylvania voters support legalizing adult-use cannabis — including 67% of Republicans and 64% of independents. The fiscal case is overwhelming. The federal landscape has shifted decisively. The medical infrastructure is ready. And still, a handful of Senate Republican leaders continue to hold the entire process hostage.

NORML regional director Chris Goldstein put it as plainly as anyone: "We are still spinning our wheels in Pennsylvania."

The wheels will keep spinning until either Senate leadership changes its mind, the caucus changes its leadership, or the voters change the composition of the chamber. Until one of those things happens, Pennsylvania will keep watching its residents — and its revenue — drive across the border.

📈 Dog Walkers

$GTBIF ( ▼ 2.5% ) Files With The Feds

Green Thumb Industries isn't waiting around to see how rescheduling plays out — it's already filing the paperwork.

The leading U.S. cannabis operator and owner of RISE Dispensaries announced it has submitted applications to the DEA to register certain state-licensed medical cannabis operations under the expedited registration pathway created by last week's rescheduling of medical marijuana to Schedule III. The move makes Green Thumb one of the first major MSOs to formally engage the new federal registration framework — a practical step that carries both symbolic and financial weight.

CEO Ben Kovler framed the filing as a natural next step: "Schedule III changes the future of medical cannabis in America, and Green Thumb is ready for what comes next." He emphasized that rescheduling "recognizes what millions of patients have known for years" and begins to address the punitive 280E tax treatment that has burdened compliant operators for over a decade.

The filing is strategically significant. Operators who submit DEA registration applications within 60 days of the rescheduling order's publication may continue operating under their existing state licenses during the review period, and the DEA has committed to processing early applications within six months. By moving quickly, Green Thumb positions itself at the front of the regulatory queue — and closer to the 280E tax relief that could materially improve its bottom line.

Green Thumb operates over 110 retail locations across 14 U.S. markets, serving both medical patients and adult-use consumers, with a branded product portfolio that includes RYTHM, incredibles, Dogwalkers, and Beboe, among others.

The company will release Q1 2026 financial results on May 6 — a call where investors will undoubtedly want to hear more about how DEA registration and 280E relief translate into actual dollars.

$TLRY ( ▼ 4.22% ) Launches More Non-Cannabis Beverages

Tilray's craft beer brand 10 Barrel Brewing is stepping outside the beer aisle — in two very different directions.

The company is launching Clean Slate and Salty Sips, two new additions to its ready-to-drink cocktail lineup that target opposite ends of the drinking occasion spectrum.

Clean Slate is 10 Barrel's first non-alcoholic functional beverage — a morning-after recovery drink infused with a Vitamin B blend, Lion's Mane for focus, Guarana and Ginseng for energy, Oregon Coast Sea Salt for hydration, and 113 mg of caffeine. Made with real grape juice, lime juice, and ginger extract, it's designed to get consumers "back in the saddle" without the booze.

Salty Sips goes the other direction — a vodka-based watermelon cocktail at just 5% ABV with only two grams of sugar, blended with real watermelon juice and a pinch of sea salt. It's squarely aimed at the better-for-you drinking trend that continues to reshape the beverage landscape.

Senior Brand Manager Moo Eakin said the launches reflect evolving consumer preferences: "We noticed a gap in our portfolio and saw that our consumers were changing."

Both products are available across the Pacific Northwest with plans to expand across the West Coast.

🗞️ The News

📺 YouTube

House Passes Farm Bill Targeting Intoxicating Hemp, Senate Up Next | TTB Presented by Flowhub

✅ Farm Bill: The House version includes language targeting Delta-8, THCA, and synthetic cannabinoids by tightening hemp's legal definition — potentially reshaping the entire hemp-derived market.

Senate Watch: The bill moves to the Senate, where Senator Rand Paul is a key figure in determining whether the hemp provisions survive or get reworked.

Rescheduling: Medical cannabis is now Schedule III, and the DEA's June 29 hearing will determine whether all marijuana follows — a pivotal moment for federal policy.

Virginia: Governor Spanberger has 30 days to sign, veto, or allow the adult-use sales bill to become law after lawmakers rejected her proposed amendments.

Pennsylvania: Legalization momentum has stalled, with the path forward uncertain despite a strong existing medical market.